Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)

Main Article Content

Alexander Stratigos
Andreas Sygros Hospital-University of Athens, Athens, Greece

Aleksandar Sekulic
Arizona Mayo Clinic, Phoenix, AZ, USA

Ketty Peris
Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy

Oliver Bechter
Department of General Medical Oncology, University Hospitals, Leuven, Belgium

Martin Kaatz
SRH Wald-Klinikum Gera GmbH, Gera, Germany

Karl Lewis
University of Colorado Hospital, Aurora, CO, USA

Nicole Basset-Segiun
Hopital Saint-Louis, Paris, France

Anne Lynn Chang
Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA

Stephanie Dalle
Department of Dermatology, HCL Cancer Institute, Lyon Cancer Research Center, Lyon, France

Almudena Fernandez Orland
Hospital Universitario Virgen Macarena, Seville, Spain

Lisa Licitra
Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Caroline Robert
Dermatology Unit, Gustave Roussy Cancer Center and Paris-Saclay University, Villejuif, France

Claas Ulrich
Charite-Universitiitsmedizin Berlin, Berlin, Germany

Axel Hauschild
Department of Dermatology, University of Kiel, Kiel, Germany

Michael Migden
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Reinhard Dummer
University Hospital Zurich, Zurich, Switzerland

Siyu Li
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Kosalai Mohan
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Ebony Coates
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Vladimir Jankovic
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Nathalie Flaschi
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Emmanuel Okoye
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Ioannis Bassukas
University of Io?nnina, Io?nnina, Greece

Carmen Loquai
Department of Dermatology, University Medical Center Mainz, Germany

Vincent De Giorgi
University of Florence, Florence, Italy

Zeynep Eroglu
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

Ralf Gutzmer
Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

Jens Ulrich
Skin Cancer Center, Department of Dermatology, Harz Clinics, Quedlinburg, Germany

Susana Puig
Hospital Cl?nic & Universitat de Barcelona and Centro de Investigaci?n Biom?dica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain

Frank Seebach
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Gavin Thurston
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Timothy Bowler
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Keywords

Locally Advanced Basal Cell Carcinoma, laBCC, Biologic, Cemiplimab, Hedgehog Inhibitor, HHI

Abstract

Abstract not available.

References

1. Sun Pharmaceuticals Industries, Inc. ODOMZO® (sonidegib) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205266s004lbl.pdf. Revised September 2017. Accessed October 12, 2020.

2. Genentech, Inc. ERIVEDGETM (vismodegib) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Revised January 2012. Accessed October 12, 2020.

3.Goodman AM et al. Oncoimmunology 2018;7:e1404217.

4. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

5. Migden MR et al. N Engl J Med. 2018;379:341–351.

6. Rischin D et al. J Immunother Cancer. 2020;8:e000775.

7. Regeneron Pharmaceuticals, Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf. Accessed July 13, 2020.

8. Inman GJ et al. Nat Commun. 2018;9:3667.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.4

Article Details

How to Cite
Stratigos, A., Sekulic, A., Peris, K., Bechter, O., Kaatz, M., Lewis, K., Basset-Segiun, N., Chang, A. L., Dalle, S., Orland, A. F., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M., Dummer, R., Li, S., Mohan, K., Coates, E., Jankovic, V., Flaschi, N., Okoye, E., Bassukas, I., Loquai, C., De Giorgi, V., Eroglu, Z., Gutzmer, R., Ulrich, J., Puig, S., Seebach, F., Thurston, G., Lowy, I., Bowler, T., & Fury, M. (2021). Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine, 5(1), s4. https://doi.org/10.25251/skin.5.supp.4
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from WC21 Clinical Dermatology Conference®: Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>